Theratechnologies Inc. Common - THTX STOCK NEWS

Theratechnologies (THTX) reported a 20% increase in consolidated sales for Q1 2022, driven by a 34.7% rise in EGRIFTA SV® sales, totaling $11.7 million. Overall revenues reached $18.6 million, up from $15.4 million in Q1 2021. R&D expenses surged by 64.6% to $8 million due to oncology program investments. The company is advancing its TH1902 clinical trial and aims for a basket study enrollment in 2022. However, delays in filing an sBLA for the F8 formulation due to supply issues were noted, alongside a net loss of $9 million, worsening from $5.9 million the prior year.

Theratechnologies (THTX) announced three poster presentations at the 2022 AACR Annual Meeting, highlighting promising preclinical data for its lead product TH1902. This drug targets sortilin-expressing cancers, showing significant tumor growth inhibition in triple-negative breast and ovarian cancer models. Key findings demonstrated an 80% reduction in tumor growth compared to standard treatments. Additionally, TH1902 exhibited superior efficacy in melanoma and endometrial cancer models. The company anticipates moving forward with further clinical trials, pending positive results.

Theratechnologies has announced it will report its first quarter financial results for fiscal 2022, ending February 28, 2022, on April 13, 2022. A conference call will follow at 8:30 a.m. (ET) to discuss the results and provide business updates. The call will feature Paul Lévesque, President & CEO, with a Q&A session for participants. Access details include a toll-free dial-in number and a webcast link. Audio replay options will be available for later listening.

Theratechnologies (THTX) announced acceptance of three poster abstracts for the 2022 AACR Annual Meeting, showcasing TH1902 preclinical data. These studies reveal the drug's ability to inhibit tumor growth in human cancer stem-like cells (CD133+) in triple-negative breast and ovarian cancers. Additional findings demonstrate TH1902's efficacy against ovarian and endometrial cancer xenografts and its inhibitory effects on melanoma growth and lung metastasis in syngeneic mice. Presentations will take place on April 11, 2022, in New Orleans.

Theratechnologies (THTX) reported a 5.7% increase in FY2021 consolidated sales, totaling $69.8 million, driven primarily by strong EGRIFTA SV® performance. Revenue guidance for FY2022 is projected between $79 million and $84 million, indicating growth of 13%-20% compared to FY2021. New patient enrollments surged 24%. The company is advancing its lead oncology asset, TH1902, towards Phase 1/Part B expansion, as it seeks out-licensing partners in Greater China. However, Trogarzo® sales declined 28.3% in Q4 2021 due to reimbursement issues in France.

Theratechnologies (THTX) announced positive results from a Phase 3 study of Trogarzo®'s IV Push method for HIV-1 treatment, presented at the virtual CROI on February 12-16, 2022. Key findings include:

• No significant pharmacokinetic differences between IV Push and IV Infusion.
• 94.7% of subjects achieved target drug concentration for both methods.
• No serious adverse events reported, with only one mild treatment-related adverse event noted.
• No difference in HIV-1 viral load or detection of anti-drug antibodies.

The FDA has accepted the supplemental Biologics License Application, with a target action date of October 3, 2022.

Theratechnologies (THTX) announces a strategic shift to an internal sales force, bolstering its U.S. operations. This initiative aims to enhance employee engagement and retention while attracting top talent. The company will integrate key account managers, medical sales liaisons, and community liaisons into its team from a partner contract sales organization. CEO Paul Lévesque emphasizes that this move will improve interactions with customers and drive growth in its commercial franchises, leveraging resumed face-to-face meetings post-COVID.

Theratechnologies Inc. (THTX) announced it will report financial results for its fourth quarter and full fiscal year 2021 on February 24, 2022. A conference call will take place at 8:30 a.m. ET the same day, hosted by CEO Paul Lévesque, to discuss these results and recent business updates. Investors can participate by dialing the provided numbers or accessing the webcast. An audio replay will be available later that day. Theratechnologies focuses on innovative therapies to address unmet medical needs.

Theratechnologies Inc. (NASDAQ: THTX) has announced the submission of a supplemental biologics license application (sBLA) to the FDA for its intravenous (IV) push form of Trogarzo^®. This submission follows positive results from the TMB-302 study, which showed no difference in pharmacokinetics between IV Push and IV Infusion. The new administration method allows infusion within 30 seconds without dilution, improving convenience for patients. No serious adverse events were reported, and secondary endpoints confirmed no difference in HIV-1 viral load.